A randomized study comparing rectally administered misoprostol versus Syntometrine combined with an oxytocin infusion for the cessation of primary post partum hemorrhage

@article{Lokugamage2001ARS,
  title={A randomized study comparing rectally administered misoprostol versus Syntometrine combined with an oxytocin infusion for the cessation of primary post partum hemorrhage},
  author={Amali U Lokugamage and Keith R. Sullivan and Iosif Niculescu and Patrick Tigere and Felix Onyangunga and Hazem el Refaey and Jagidesa Moodley and C. H. Rodeck},
  journal={Acta Obstetricia et Gynecologica Scandinavica},
  year={2001},
  volume={80}
}
Background. Post partum hemorrhage is a major cause of maternal death, particularly in developing countries, and most cases are due to an atonic uterus. Hemorrhage can occur despite active management of the third stage of labor. Presently, misoprostol (Cytotec, Searle Pharmaceuticals) is the only thermostable uterotonic agent potentially available which would be economically beneficial for developing countries where refrigeration of drugs poses a problem. The objective of the study was to… Expand

Paper Mentions

Interventional Clinical Trial
This document defines the Clinical Investigation Protocol for a study designed to determine whether blood loss after spontaneous vaginal delivery is altered by the addition of… Expand
ConditionsPostpartum Hemorrhage
InterventionBiological
Rectal misoprostol versus intramuscular oxytocin for prevention of post partum hemorrhage.
TLDR
Rectal misoprostol is as effective as intravenous oxytocin in preventing postpartum hemorrhage with the similar incidence of side effects and is worthwhile to be used as a uterotonic agent for the routine management of third stage of labor. Expand
Rectal misoprostol versus oxytocin in the management of the third stage of labour.
TLDR
The utility of misoprostol as a safe and effective uterotonic for use in the rural and remote areas of developing nations where other pharmacologic agents may be less feasible is confirmed. Expand
Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women not exposed to oxytocin during labour: a double-blind, randomised, non-inferiority trial
TLDR
This trial established whether sublingual misoprostol was similarly efficacious to intravenous Oxytocin for treatment of post-partum haemorrhage in women not exposed to oxytocin during labour. Expand
Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women receiving prophylactic oxytocin: a double-blind, randomised, non-inferiority trial
TLDR
Misoprostol is clinically equivalent to oxytocin when used to stop excessive post-partum bleeding suspected to be due to uterine atony in women who have received oxytoc in prophylactically during the third stage of labour. Expand
Misoprostol as an adjunct to standard uterotonics for treatment of post-partum haemorrhage: a multicentre, double-blind randomised trial
TLDR
Findings from this study do not support clinical use of 600 microg sublingual misoprostol in addition to standard injectable uterotonics for treatment of post-partum haemorrhage. Expand
COMPARISON OF THE MEAN BLOOD LOSS WITH SUBLINGUAL MISOPROSTOL VERSUS INTRAVENOUS OXYTOCIN IN LOW-RISK FEMALES UNDERGOING NORMAL VAGINAL DELIVERY
Background: Oxytocin and Misoprostol are considered to be the two most effective drugs in preventing PPH. But contradiction in literature was observed. So to confirm whether misoprostol is moreExpand
Misoprostol to treat postpartum haemorrhage: a systematic review
TLDR
The aim of this review was to determine the route of administration and dosage of misoprostol most likely to be effective in the treatment of PPH and identify randomised controlled trials that compared misop frostol with any appropriate control groups. Expand
Misoprostol in addition to routine treatment of postpartum hemorrhage: A hospital-based randomized-controlled trial in Karachi, Pakistan
TLDR
A 600 mcg dose of misoprostol given sublingually shows promise as an adjunct treatment for PPH and its use should continue to be explored for its life-saving potential in the care of women experiencing PPH. Expand
Le misoprostol dans le traitement curatif des hémorragies du post-partum
TLDR
Misoprostol has uterotonic properties that have led to its occasional off-label use in the treatment of postpartum hemorrhage, by rectal or sublingual administration, as an alternative to sulprostone. Expand
Treatment of postpartum hemorrhage with misoprostol
  • Medicine
  • International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • 2012
TLDR
Misoprostol was non-inferior to oxytocin at controlling active bleeding within 20 minutes (90% vs 89%) and preventing additional blood loss of 300 mL or greater (31% vs 34%) and results suggested that misop frostol may be more effective than Syntometrine/Syntocinon for treatment of PPH. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 10 REFERENCES
Randomized comparison of rectal misoprostol with Syntometrine for management of third stage of labor.
TLDR
There was a significant difference in the pre-delivery blood pressure of the two groups because of the non-protocol exclusion of women with elevated blood pressure allocated to receive Syntometrine. Expand
Rectally administered misoprostol for the treatment of postpartum hemorrhage unresponsive to oxytocin and ergometrine: a descriptive study.
TLDR
Rectally administered misoprostol appears to be an effective treatment for postpartum hemorrhage unresponsive to oxytocin and ergometrine; therefore, it might be an alternative to parenteral prostaglandins or at least minimize the number of women requiring this invasive treatment. Expand
Randomised controlled trial of oxytocin alone versus oxytocin and ergometrine in active management of third stage of labour.
TLDR
There are few advantages but several disadvantages for the routine use of oxytoxinergometrine when prophylactic active management of the third stage of labour is practised and further investigation of dose-response for oxytocin is warranted. Expand
Early abortion induction by a combination of mifepristone and oral misoprostol: a comparison between two dose regimens of misoprostol and their effect on blood pressure
TLDR
The efficacy of 800 μg misoprostol (a PGE1 analogue) when administered to women pretreated with mifepristone for early pregnancy termination and the impact of these regimens on blood pressure was investigated. Expand
Absorption Kinetics of Misoprostol With Oral or Vaginal Administration
TLDR
The observation of the prolonged serum concentrations in the vaginal group suggests that vaginal administration could be dosed at longer intervals than oral, and there are significant differences in the pharmacokinetics of misoprostol administered by vaginal and oral routes that may explain the difference observed in clinical efficacy. Expand
The misoprostol third stage of labour study: a randomised controlled comparison between orally administered misoprostol and standard management
TLDR
This study aims to compare misoprostol with standard oxytocic regimens in the prevention of postpartum haemorrhage and find out if these regimens are effective in women with high-risk pregnancies. Expand
Postpartum haemorrhage: its contribution to maternal mortality.
TLDR
Postpartum haemorrhage is the major cause of maternal mortality in the developing world and the causes and strategies for its prevention are discussed. Expand
The postpartum period: the key to maternal mortality
  • X. Li, J. Fortney, M. Kotelchuck, L. Glover
  • Medicine
  • International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • 1996
TLDR
In developing countries, hemorrhage, pregnancy‐induced hypertension complications, and obstetric infection are commonest causes of postpartum deaths, and the risk remains significant until the second week after delivery. Expand
Pre-eclampsia/eclampsia syndrome
  • S Afr J Contin Med Educ
  • 1997
World Health Organisation. Maternal mortality: a global factbook
  • WHO
  • 1991